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Abstract: Tropical forests constitute prolific sanctuary of unique floral diversity and potential 20 
medicinal sources, however, many of them remain unexplored. The scarcity of rigorous scientific 21 
data on the surviving Mascarene endemic taxa renders bioprospecting of this untapped resource of 22 
utmost importance. Thus, in view of valorising the native resource, this study has as objective to 23 
investigate the bioactivities of endemic leaf extracts. Herein, seven Mascarene endemic plants leaves 24 
were extracted and evaluated for their in vitro antioxidant properties and antiproliferative effects on 25 
a panel of cancer cell lines using MTT and clonogenic cell survival assay. Flow cytometry and comet 26 
assay were used to investigate the cell cycle and DNA damaging effects, respectively. Bioassay 27 
guided-fractionation coupled with LC-Mass spectrometry (MS), gas chromatography-MS, and 28 
nuclear magnetic resonance spectroscopy analysis were used to identify the bioactive compounds. 29 
Among the seven plants tested, Terminalia bentzoë was comparatively the most potent antioxidant 30 
extract with significantly (p < 0.05) higher cytotoxic activities. T. bentzoë extract further selectively 31 
suppressed the growth of human hepatocellular carcinoma cells and significantly halted the cell 32 
cycle progression in G0/G1 phase, decreased the cells replicative potential and induced significant 33 
DNA damage. Ten phenolic compounds including punicalagin and ellagic acid were identified and 34 
likely contributed to the extract potent antioxidant and cytotoxic activities. These results established 35 
a promising basis for further in-depth investigations on the potential use of T. bentzoë as supportive 36 
therapy in cancer management.  37 
Keywords: Terminalia bentzoë; Mascarene endemic; cytotoxicity; antioxidant; cell cycle arrest; 38 
phenolics; bioassay-guided fractionation 39 
1. Introduction 40 
The plant kingdom is known to be a prolific sanctuary of phytochemicals with unique 41 
therapeutic potential. At least 25 % of the 1562 clinical drugs approved by the US Food and Drugs 42 
Administration are known to have been emanated from terrestrial plants [1,2]. Moreover, an estimate 43 
of about 28187 plant taxa, globally, are documented to have medicinal values with over 3000 species 44 
reported with the ethnomedicinal application against cancer [3,4]. The continued dependence of 45 
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mankind on plants was further evidenced during the recent outbreak of the COVID-19 pandemic 46 
whereby, herbal medicines were used in an attempt to mitigate the symptoms of the novel 47 
coronavirus infection [5–7].  48 
Madagascar and its neighboring islands in the Western Indian Ocean regions are known as 49 
biodiversity hotspots [8]. Undoubtedly, untapped endemic plant species from these niche areas 50 
broadened the structural variation of novel chemotypes [9,10]. The tropical forest of Madagascar was 51 
once acknowledged as a fertile source of economically valuable plants with pharmacologically active 52 
ingredients [11]. Indeed, the anticancer drugs vinblastine and vincristine were derived from the 53 
Madagascan endemic Catharanthus roseus (Apocynaceae) [12]. Certainly, the market value of 54 
vincristine alone was estimated to be 15 million USD per kilogram, in the year 2016 [13].  55 
    Phytogeography investigations revealed that the Mascarene endemic plants islands have their 56 
ancestral lineages traced back from Madagascar [14]. As such, the unique floral biodiversity of 57 
Mauritius is expected to possess similar medicinal and therapeutic prolificacy as the Madagascan 58 
rain forest. However, instead of conserving such valuable biodiversity, human activities are pushing 59 
endemic taxa towards an unprecedented extinction crisis. In less than 400 years of human settlement, 60 
Mauritius has witnessed the shrinking of its native forest to around 5 % of the original cover, leading 61 
to the permanent loss of 30 (10.9 %) of its endemic plant species and driving 81.7  % of the remnant 62 
endemic taxa on the brink of extinction [15–17]. For instance, fewer than 500 adults trees of Terminalia 63 
bentzoë (L.) L.f. subsp. bentzoë is recorded in the wild, defining the species survival as vulnerable, as 64 
per the IUCN red list criteria [18]. Nevertheless, the remnant areas of the pristine forest are still home 65 
to a plethora of endemic flora rich in high genetic diversity representing interesting sources for 66 
complementary and alternative medicine, nutraceuticals as well as pharmaceutical leads [16]. 67 
     Initiation and progression of cancer are involved in oxidative stress via DNA damage and 68 
increase of DNA mutations. Conventional chemo- and radiotherapy caused cancer cell death often 69 
through generation of reactive oxygen species (ROS), but also unfortunately leading to severe side 70 
effects. It is highly desired to develop more effective therapies with less toxic effects [19]. Plant 71 
polyphenols exert anticarcinogenic activity by interfering with the different hallmarks of cancer, 72 
including sustained tumor cell proliferation, angiogenesis and apoptotic cell death through various 73 
signaling pathways [19,20]. Polyphenolics can also behave as antioxidants thereby maintaining the 74 
integrity of DNA from oxidative stress attack and prevent the initiation stage of carcinogenesis 75 
[21,22]. 76 
     The tropical island of Mauritius is known for its endemic biodiversity richness [8]. However, 77 
human activities on the island have provoked the irreversible loss of a considerable fraction of this 78 
genetic resource. For instance, in less than four centuries, Mauritius has lost 95 % of its pristine forest 79 
cover accounting for the extinction of 10.9 % of the island endemic flora [23]. The scarcity of rigorous 80 
scientific data on the surviving endemic taxa renders bioprospecting of this untapped resource of 81 
utmost importance. With this in mind, and in view of providing solid foundations to enforce stringent 82 
conservation policies, the in vitro antioxidant propensities of leaf extracts from seven plants endemic 83 
to Mascarene islands were investigated, in relation to their polyphenolic content. The plants under 84 
study have documented traditional uses against ailments ranging from dermatological conditions, 85 
asthma to infectious diseases (Table 1). The cytotoxic effect of Terminalia bentzoë, on a panel of cancer 86 
cell lines, and its ability to impede the cell cycle progression in hepatocellular carcinoma (HepG2) 87 
cells were determined. The bioactive constituents in T. bentzoë leaf extract were characterised 88 
following bioassay-guided fractionation. 89 
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2. Materials and Methods 90 
2.1. Plant material and preparation of total extracts. 91 
Healthy fresh leaves of seven Mascarene endemic plants were collected in Mauritius and 92 
deposited at the Mauritius herbarium, where plant species were authenticated by the botanist (Table 93 
1). The leaves were air-dried followed by exhaustive maceration with aqueous methanol (80 %, v/v) 94 
and freeze-dried as described previously [24]. The assay results were expressed in terms of the 95 
lyophilised weight of extracts. 96 
2.2. Estimation of polyphenolic contents. 97 
The total phenolic, flavonoid, and proanthocyanidin level in the crude extracts were estimated 98 
using the Folin-Ciocalteu assay, aluminium chloride assay and HCl/Butan-1-ol assay as described 99 
[24]. 100 
2.3. In-vitro antioxidant capacities of extracts. 101 
The antioxidant potential of the extracts was investigated according to reported methods [24,25]. 102 
Extract vehicle and gallic acid (or otherwise stated) were used as negative and positive controls 103 
respectively. The percentage activity of the extracts was calculated relative to the negative control. 104 
GraphPad Prism 6 software (GraphPad Inc., USA) was used to plot the dose-response curves and to 105 
generate the half-maximal inhibitory concentration (IC50) values. All experiments were performed in 106 
triplicates in three independent assays. The results were expressed as mean ± SEM. 107 
 108 
     2.3.1. Ferric reducing antioxidant potential assay 109 
The final reaction volume of 3.4 mL of the ferric reducing antioxidant power assay contained 100 µL 110 
of extract and 300 µL of water followed by addition of 3 mL FRAP reagent. The FRAP reagent was 111 
prepared immediately before use by mixing 100 mL of 0.25 M acetate buffer (pH 3.6), 10 mL of 20 112 
mM ferric chloride (source of Fe3+) and 10 mL of 10 mM 2,4,6-tripyridyl-s-triazine. After incubating 113 
the mixture for 4 minutes at ambient temperature, the absorbance was read at 593 nm against a blank. 114 
Results were reported as in mmol Fe2+. 115 
 116 
2.3.2. 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay 117 
The DPPH assay protocol involved mixing varying concentrations, between 0 to 25 µg/mL, of 100 µL 118 
of the methanolic extract with 200 µL of 100 µM methanolic DPPH and absorbance were read at 492 119 
nm, 30 minutes post-incubation at ambient temperature.  120 
 121 
2.3.3. Iron chelating assay 122 
The reaction mixture for iron-chelating activity contained 40 µL of plant extract (concentrations 123 
between 0 to 10 mg/mL), 10 µL of FeCl2⋅4H2O (0.5 mM) and 150 µL of distilled deionized water. The 124 
mixture was incubated at ambient temperature for 5 minutes, before the addition of 10 µL of ferrozine 125 
(2.5 mM) and the absorbance was read at 562 nm.  126 
 127 
2.3.4. Superoxide scavenging assay 128 
The final 250 µL reaction volume for superoxide anion scavenging assay contained 25 µL of 129 
plant extract (concentrations between 0 to 300 µg/mL), 100 µL of 156 µM of nitroblue tetrazolium and 130 
100 µL of 200 µM beta-nicotinamide adenine dinucleotide reduced disodium salt hydrate and 30 µL 131 
of phenazine methosulphate. The absorbance was read at 560 nm following 30 minutes incubation at 132 
25 ˚C.  133 
 134 
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Table 1. The investigated Mascarene endemic plant species. 135 
Species Family Vernacular names Ethnomedicinal uses   [16] Collection site Collection date 
Mauritius 
herbarium 
accession code 
% 
Yield 
Antirhea borbonica 
J.F.Gmel Rubiaceae 
Bois lousteau, 
Bois d’oiseau 
Astringent, diarrhoea, dysentery, 
stop bleeding, promote wound 
repair, skin diseases, tambave, 
Urinary tract infections 
Gaulettes Serrées 14-Oct-2014 MAU 0009462 5.53 
Dictyosperma album 
(Bory) H. Wendl. & Drude 
ex Scheff var. conjugatum 
H. E. Moore & Guého 
Arecaceae Palmiste blanc Not described Réduit, Joseph Guého Arboretum 19-Aug-2014 MAU 0016674 8.52 
Erythroxylum 
sideroxyloides Lam 
Erythroxylaceae Bois de ronde Renal stones 
Lower Gorges 
National Park, 
'Morne Sec' 
15-Oct-2014 MAU 0016542 13.81 
Ficus mauritiana Lam Moraceae Figuier du pays Not described Gaulettes Serrées 14-Nov-2014 MAU 0011002 3.10 
Hancea integrifolia 
(Willd.) S.E.C. Sierra, 
Kulju & Welzen 
Euphorbiaceae Bois pigeon Clean the blood and improve blood circulation, tonic. Gaulettes Serrées 14-Nov-2014 MAU 0016431 10.42 
Stillingia lineata Muell. 
Arg Euphorbiaceae 
Fangame; Bois 
de lait; 
Tanguin de 
pays 
Eczema, skin disease 
Lower Gorges 
National Park, 
'Morne Sec' 
27-Nov-2014 MAU 0016545 6.28 
Terminalia bentzoë (L.) L.f. 
subsp. bentzoë Combretaceae Bois benjoin 
Asthma, antipyretic, antimalarial, 
chills, dysentery, diarrhoea, 
depurative, emmenagogue, 
haemorrhages, Sexually 
transmissible diseases 
Réduit, Joseph 
Guého Arboretum 7-Oct-2014 MAU 0016557 7.29 
136 
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2.3.5. Nitric oxide scavenging assay 137 
The nitric oxide radical scavenging activity was conducted in a 96-well plate. 50 µL of aqueous 138 
extract (0 to 100 µg/mL) and 100 µL of 5 mM of sodium nitroprusside (in phosphate saline buffer, pH 139 
7.4) was incubated at 25 ˚C for 150 minutes. After incubation, 125 µL of the reaction mixture was 140 
transferred to another 96-well plate, to which 100 µL of 0.33 % sulfanilic acid in 20 % glacial acetic 141 
acid was added. After 5 minutes, 100 µL of 0.1 % of N-1-napthyethylenediamine dihydrochloride 142 
was added and the pink coloration formed was read at 546 nm.  143 
 144 
2.3.6. Deoxyribose degradation inhibitory assay 145 
The deoxyribose degradation inhibitory assay protocol was optimised to a 24-well microtiter 146 
plate format. Each well contained 50 µL of aqueous extract, 50 µL of 1 mM EDTA, 100 µL of 500 µM 147 
FeCl3, 50 µL of 1 mM ascorbic acid, 50 µL of 10 mM hydrogen peroxide, 100 µL of 100 mM KH2PO4-148 
KOH buffer (pH 7.4) and 100 µL of 15 mM 2-deoxyribose. The reaction mixture was incubated at 37 149 
˚C for 90 minutes. At the end of the incubation period, 500 µL of 10 % (w/v) trichloroacetic acid 150 
followed by 500 µL of 1% (w/v) thiobarbituric acid were added to each well and the solutions were 151 
heated in a water bath at 80 ˚C for 20 minutes to develop the pink chromogen. The absorbance of the 152 
reaction mixture was read at 532 nm, both before and after incubation. Results were given in mg 153 
lyophilised extract/mL. 154 
2.4. Human cell lines and culture conditions 155 
Human liposarcoma cells (SW872), human lung carcinoma cells (A549), human hepatocellular 156 
carcinoma cells (HepG2), and human ovarian carcinoma cell lines OVCAR-4 and OVCAR-8 were 157 
purchased from American Type Culture Collection (USA). Human ovarian epithelial (HOE) cells 158 
immortalized using SV40 large T antigen was obtained from Applied Biological Materials Inc 159 
(Canada). All cell lines, except the ovarian cell lines, were cultured in Dulbecco's Modified Eagle's 160 
Medium. Roswell Park Memorial Institute (RPMI) 1640 medium was used in the case of ovarian cell 161 
lines. Culture medium was supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 100 162 
U/L streptomycin-penicillin. Cells were grown in a humidified atmosphere of 5 % carbon dioxide 163 
and 95 % humidity at 37 ˚C. 164 
2.5. Cell-based assays 165 
The viability of the investigated cells treated with test samples was evaluated using the methyl 166 
thiazolyl diphenyl-tetrazolium bromide (MTT) cell viability assay. Following overnight 167 
acclimatisation of cells in 96-well plate, cells were treated with test samples for 48 hours and assayed 168 
for different parameters. For 96-well plate, the seeding densities for cancer cell lines and HOE cells 169 
were 5 x 103 cells and 2 x 103 cells per well, respectively. All experiments were performed in triplicates 170 
(unless otherwise specified) in three independent assays. To compare the chemotherapeutic potential 171 
of the active extracts, the cytotoxicity of the extracts/purified compounds was evaluated against, 172 
etoposide, a clinically used oncologic agent.  173 
2.5.1. MTT viability assay 174 
The MTT assay was performed as previously described [26]. The percentage cell viability relative 175 
to DMSO control (0.025 % v/v, final concentration) was calculated and the IC50 value determined 176 
using GraphPad Prism 6 software (GraphPad Inc., USA). 177 
2.5.2. Clonogenic cell survival assay 178 
The effect of T. bentzoë leaf extract on the cell reproductive death was assessed by clonogenic cell 179 
survival assay according to reported methods, with slight modifications [27,28]. HepG2 cells were 180 
seeded in a 6-well plate (500/well) and allowed to attach overnight. Following 48 hours treatment 181 
period with extract/ control, the media was replaced with fresh complete culture media and cells 182 
were grown under standard recommended culture conditions for an additional 7 days to allow large 183 
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colonies formation. Colonies were then fixed with 4 % paraformaldehyde for 30 minutes and stained 184 
with 0.5 % (w/v) crystal violet. The individual wells were imaged using a digital camera and the 185 
colonies counted using ImageJ software (the US, National Institute of Health). The cytotoxic effect 186 
was expressed as the percentage of surviving colonies relative to untreated control. 187 
2.5.3. Single cell gel electrophoresis 188 
Comet assay was carried out according to the method described [29,30] with minor 189 
modifications. Briefly, 30 µL of pre-treated cells were mixed with 70 µL of 1 % (w/v) low melting 190 
agarose (LMA) and 40 µL of the cell-LMA mixture was placed on frosted microscope slides pre-191 
coated with 1.5 % normal melting agarose. A coverslip was placed on top of the cell-LMA mix and 192 
allowed to solidify at 4°C for 1 hour in dark. Following solidification, the coverslip was gently slid 193 
off and the slides were immersed in pre-chilled lysis buffer (2.5 M NaCl, 0.1 M EDTA, 10 mM Tris 194 
base, 1% v/v Triton X-100 (added 30 minutes before use), pH 10, 4 °C) for 1 hour in dark. Following 195 
this period, the excess lysis solution was drained and the slides were submerged in electrophoresis 196 
buffer (0.2 M NaOH, 1 mM EDTA, pH 13, 4 °C) for 30 minutes in dark, to allow the DNA to unwind.  197 
Electrophoresis was conducted for 30 minutes at 30 volts and 350 mA. The gels were neutralized 198 
by immersing in pre-chilled neutralisation buffer (0.4 Tris-HCL, pH 7.5, 4 °C) for 10 minutes in dark. 199 
The slides were washed in distilled water, fixed with 4 % formalin solution for 20 minutes and 200 
allowed to air-dry overnight. The slides were stained with Hoechst 33342 (1 µg/mL), air-dried in dark 201 
and visualised at 200 X magnification in DAPI, using EVOS fluorescence microscope (Life 202 
Technologies). Damaged DNA was measured for 100 randomly selected cells (for each independent 203 
experiment) using the Comet Assay IV 4.3.1 (Perceptive instrument, UK).  204 
2.5.4. Flow cytometric analysis 205 
Apoptosis/necrosis analysis was performed on HepG2 cells after 48 hours treatment by flow 206 
cytometry (Beckman Coulter's CytoFLEX and Cytexpert software)  using Annexin V-FITC and 207 
Propidium iodide (PI) double staining as described in a previous study [31]. Cell cycle analysis was 208 
performed using propidium iodide for DNA staining as described [32]. Percentage of cells in different 209 
phases (GO/G1, S and G2M phases) were quantified from propidium iodide fluorescence intensity-210 
area (PI-A) histograms corresponding to the DNA content of HepG2 cells. 211 
2.5.5. MTT-guided fractionation and identification of bioactive molecules  212 
The total extract of T. bentzoë was solubilised in distilled water and sequentially partitioned with 213 
ethyl acetate, followed by n-butanol. Each fraction was dried and their cytotoxicity evaluated against 214 
SW872, A549, HepG2 using the MTT cell viability assay. The butanol fraction being selective towards 215 
HepG2 cells was subjected to Sephadex LH-20 column chromatography (30 cm X 2.1 cm internal 216 
diameter) and eluted with water, water: methanol (3:1 v/v, 1:1 v/v and 1:3 v/v respectively), methanol 217 
and acetone. The flow rate was maintained at 1.5 mL/min.  Guided by the cytotoxicity against 218 
HepG2 cells and purity profile, potent sub-fraction was further fractionated using semi-preparative 219 
HPLC column. The crude extract and thereof derived purified fractions were analysed by extensive 220 
spectroscopic methods including GC-MS, LC-MS, HPLC, 1H-NMR and 13C-NMR (Supporting 221 
Information). For analytical HPLC, the concentration of standards in the crude extract was 222 
determined from the linear regression of the analytical standards curve namely y = 12.317 x, R2 = 223 
0.9996: gallic acid and y = 16.066 x, R2 = 0.9992: methyl gallate.  224 
2.6. Statistical analysis 225 
Statistical analyses were performed using GraphPad Prism 6 software (GraphPad Inc., San 226 
Diego, California). The mean values among extracts were compared using One-Way ANOVA. 227 
Student t-test and/or Tukey’s multiple comparisons as Post Hoc test was used to determine 228 
significances in mean phytochemicals, antioxidants and cytotoxic activities among different species. 229 
All charts were generated using GraphPad Prism 6 software (GraphPad Inc., San Diego, California). 230 
 7 of 24 
 
3. Results 231 
3.1. Estimation of polyphenols level in the investigated leaf extracts. 232 
The phenolic content varied significantly among the seven leaf extracts under study (p < 0.05) 233 
with amounts ranging between 70.2 ± 4.72 mg and 385 ± 24.1 mg gallic acid equivalent/g. Total 234 
flavonoid levels ranged between 2.43 ± 0.06 mg and 12.9 ± 0.45 mg quercetin equivalent/g. Based on 235 
the spectrophotometric assay results, the estimated level of phenolics and flavonoids were 236 
significantly highest (p < 0.05) in T. bentzoë leaf extract as compared to the other investigated leaf 237 
extracts (Table 2). While the proanthocyanidin content prevailed in E. sideroxyloides leaf, both S. 238 
lineata leaf and T. bentzoë leaf had a remarkably negligible amount of proanthocyanidin detected by 239 
the butanol/HCl assay.  240 
3.2. In-vitro antioxidant activities of the investigated leaf extracts. 241 
An array of five analytical models was used to benchmark the antioxidant potential of the 242 
investigated leaf extracts. The Mascarene endemic plant leaf extracts exhibited a varying degree of 243 
activities in the different antioxidant assays. All extracts showed a dose-dependent metal chelating 244 
and free radical scavenging activity (Table 2). In terms of iron chelation, all the extracts were weak 245 
chelator compared to EDTA with an IC50 value of 0.01 ± 0.00 mg/mL (23.6 ± 0.22 µM) (p ≤ 0.05). As 246 
depicted in Table 2, among the seven accessions of plants, T. bentzoë showed the most effective 247 
antioxidant potential in all the five antioxidant assays. Thus, the free radical quenching activity of T. 248 
bentzoë was further evaluated in hydroxyl radical scavenging assay. T. bentzoë (IC50 = 0.25 ± 0.03 249 
mg/mL) exhibited a significantly (p < 0.0001) greater degree of protection against Fenton-mediated 250 
oxidative damage to 2-deoxyribose sugar moiety as compared to gallic acid (IC50 = 1.65 ± 0.09 mg/mL). 251 
 252 
3.3. Effect of T. bentzoë leaf extract on cell survival 253 
To assess the antiproliferative properties of T. bentzoë leaf extract on cancer cells, first, the 254 
influence of the extracts on the cell viability of five cancer cell lines notably, SW872, A549, HepG2, 255 
Ovcar-4 and Ovcar-8 cells, were investigated using the MTT assay. T. bentzoë suppressed the growth 256 
of all cancer cell lines in a dose-dependent manner. However, the dose of extract required to reach 257 
the half-maximal inhibitory concentration differed considerably among the various cancer cell types. 258 
The cytotoxicity of T. bentzoë was also evaluated against the non-malignant human ovarian epithelial 259 
(HOE) cells and the IC50 value obtained (Table 3). HepG2 cells were more sensitive to T. bentzoë 260 
treatment (selective index value 2.4 compared to HOE cells) (Table 3). At 48 hours of exposure, the 261 
highest concentration of T. bentzoë extract (100 µg/mL) reduced HepG2 cell viability to 20 % as 262 
compared to untreated control cells (Supplementary figure S1 A). Subsequently, the effect of T. 263 
bentzoë extract on the replicative ability of HepG2 cells was evaluated using the clonogenic cell 264 
survival assay. T. bentzoë treatment significantly (ρ < 0.0001) reduced the number of surviving HepG2 265 
colonies as compared to untreated control cells (Figure 1). 266 
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Table 2. Phenolic content and antioxidant potential of investigated leaf extracts. 267 
Extract  Total phenolics1 
Total 
flavonoids2  
Total 
proanthocya
nidins3 
FRAP4 
Iron  
chelating  
activity5 
DPPH  
Scavenging  
activity6 
Superoxide  
scavenging  
activity6 
Nitric oxide  
scavenging  
activity6 
A. borbonica 70.2 ± 4.72e 3.15 ± 0.07d,e 5.71 ± 0.09e 3.32 ± 0.16d,e,**** 4.05 ± 0.26b,c,**** 11.2 ± 1.63d,**** 19.0 ± 2.46d,**** 80.3 ± 29.0b,** 
D. album 75.7 ± 5.22d 2.43 ± 0.06f 30.9 ± 0.58c 2.21 ± 0.05e,**** 4.83 ± 1.49c,d,**** 7.89 ± 0.13c,**** 32.7 ± 1.16f,**** 68.0 ± 10.0a,* 
E. 
sideroxyloides 182 ± 10.5
b 3.62 ± 0.13d 121 ± 3.25a 9.14 ± 0.85b,**** 1.46 ± 0.02a,**** 4.44 ± 0.26b,**** 12.7 ± 0.65c,**** 24.3 ± 1.39a 
F. mauritiana 133 ± 2.36c 10.4 ± 0.21b 85.7 ± 2.38b 5.38 ± 0.01c,**** 0.43 ± 0.01a,**** 5.35 ± 0.23b,**** 24.2 ± 0.44e,**** 87.08 ± 28.9b,*** 
H. integrifolia 142 ± 4.91c 2.75 ± 0.06e,f 18.4 ± 0.78d 9.37 ± 0.29b,**** 0.78 ± 0.01a,**** 4.16 ± 0.16b,**** 9.55 ± 0.78b,*** 68.49 ± 37.5a,b,** 
S. lineata 97.7 ± 3.36d 6.61 ± 0.19c ND 4.53 ± 0.02c,d,**** 6.45 ± 0.02d,* 4.04 ± 0.17a,b,**** 3.81 ± 0.48a 68.5 ± 42.9b,** 
T. bentzoë 385 ± 24.1a 12.9 ± 0.45a ND 18.2 ± 0.01a,**** 0.10 ± 0.00a,**** 2.65 ± 0.14a,*** 5.20 ± 0.53a 9.74 ± 3.13a 
Gallic acid - - - 24.8 ± 0.22 8.00 ± 0.04                        (47.0 ± 0.23 mM) 
0.62 ± 0.05                           
(4.18 ± 0.32 µM) 
5.52 ± 0.11                          
(31.4 ± 0.84 µM) 
9.61 ± 1.75                     
(68.0 ± 13.9 µM) 
1Values are expressed as mg of gallic acid equivalent (GAE)/g, 2values are expressed as mg of quercetin equivalent (QE)/g; 3values are expressed as mg of cyanidin 268 
chloride equivalent (CCE)/g; 4Values are expressed in mmol Fe2+; 5IC50 values are expressed in mg/ml; 6IC50 values are expressed in µg/ml; Data represent mean ± 269 
standard error of mean (n=3). ND = Not detected. Different letters between rows in each column represent significant differences between extracts (p < 0.05). Asterisks 270 
represent significant differences between extracts and gallic acid (positive control), * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 271 
 272 
Table 3. Cytotoxicity (IC50 µg/ml) of T. bentzoë against human cancer cell lines. . 273 
Extracts SW872 A549 HepG2 Ovcar-4 Ovcar-8 HOE 
T. bentzoë 45.4 ± 1.8**** 96.8 ± 4.9**** 22.8 ± 1.3**** 30.1 ± 2.3 38.5 ± 4.2 55.5 ± 9.1 
Etoposide 2.5 ± 0.2 6.8 ± 0.7 1.7 ± 0.2 NA NA 1.5 ± 0.1 
 274 
Data represent mean calculated IC50 values with a standard error of the mean (n=3). NA= Etoposide at 1 µg/ml. Inhibited above 80 % cancer cell growth, indicating 275 
a much lower concentration is required for determination of IC50 value. Asterisks represent significant differences between T. bentzoë and etoposide (positive control), 276 
**** p ≤ 0.0001. 277 
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 278 
Figure 1. HepG2 cells were treated with indicated concentrations (µg/mL) of test extracts for 48 hours 279 
and subsequently allowed to grow into colonies for 14 days. After 14 days, the colonies were stained 280 
with 0.1 % crystal violet and the images of the wells were captured using a digital camera. The 281 
colonies were counted using Image J software. Each experiment was performed three times. Asterisks 282 
represent significant differences between extracts treatments and untreated control, **** p ≤ 0.0001. 283 
3.3. Genotoxic effect of T. bentzoë extract in HepG2 cells. 284 
DNA damage induced by T. bentzoë leaf extract was assessed in HepG2 cells by the alkaline 285 
comet assay. Treatment with 10 µg/mL T. bentzoë leaf extract for 24 hours resulted in the induction of 286 
significant (p ≤ 0.0001) DNA damage in HepG2 cells as compared to untreated control cells. The 287 
occurrence of DNA damaged was scored in terms of tail length, tail intensity and olive tail moment 288 
of cell cultures by comet assay software (Table 4). The increased olive tail moment in response to T. 289 
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bentzoë treatment was 4-fold higher than that of untreated control cells. Cells treated with 200 µM 290 
H2O2 for 30 minutes, was used as a positive control.  291 
Table 4. Tail length, tail intensity and olive tail moment of H2O2 and T. bentzoë treated HepG2 cells. 292 
Extracts Tail length (µm) Tail intensity Olive tail moment 
Negative control (Culture medium) 32.8 ± 0.3 0.8 ± 0.1 0.2 ± 0.0 
Terminalia bentzoë 38.5 ± 0.4**** 3.7 ± 0.2**** 0.8 ± 0.0**** 
Positive control (200 µM H2O2) 90.8 ± 7.2**** 46.8 ± 2.6**** 14.1 ± 0.6**** 
Asterisks represent significant differences between extracts and untreated control, **** p ≤ 0.0001. 293 
3.4. T. bentzoë induced cell death.  294 
The proportion and distribution of HepG2 cells stained by annexin V-FITC and PI after 48 hours 295 
of exposure to T. bentzoë extract are illustrated in figure 2A and supplementary figure S2. The results 296 
indicated that, at a concentration equivalent to 10 µg/mL and 20 µg/mL, the distribution pattern of 297 
the cell populations in the different quadrants (supplementary figure S2) is similar to that of DMSO 298 
control. However, exposure of HepG2 cells for 48 hours at 40 µg/mL, stimulated a significant increase 299 
in annexin V (1.41 fold, p < 0.01) and propidium iodide (1.52 fold, p < 0.001) fluorescence compared 300 
to the control. This increase is notably reflected in a higher percentage of necrotic cells necrotic cells 301 
(11.7%, p < 0.01) compared to the DMSO control (4.33%), indicating apoptotic/ necrotic cell death at 302 
this test concentration. Etoposide significantly (p < 0.001) increased the proportion of cells undergoing 303 
apoptosis (between 10 and 12 %)/ necrosis (between 16 and 21 %) at all three test doses, relative to 304 
DMSO control. 305 
3.5. Cell cycle progression and T. bentzoë. 306 
Flow cytometric analysis of DNA content, of HepG2 cells treated with test extracts for 48 hours, 307 
allowed the determination of the percentage of the cell population in each phase of the cell cycle. As 308 
emphasised in figure 2B and supplementary figure S3, exposure of HepG2 cells to 40 µg/mL of T. 309 
bentzoë induced G0/G1 cell cycle arrest by increasing the cell population in G0/G1 (until 73.1 ± 1.76 %, 310 
p < 0.01 vs. ctrl) to the detriment of the G2/M phase (until 17.92 ± 1.76 %, p < 0.001 vs. ctrl). In contrast, 311 
treatment with 4 µg/mL etoposide led to the accumulation of G2/M cell fraction (until 53.6 ± 5.55 %) 312 
to the detriment of G0/G1 cells fraction (42.2 ± 6.25 %) suggesting G2/M arrest of HepG2 cell 313 
progression.  314 
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 315 
Figure 2. Effect of Terminalia bentzoë and etoposide on HepG2 cells as analysed by flow cytometry. (A) 316 
Annexin V-FITC/PI staining of HepG2 cells after 48 hours treatment and (B) cell cycle progression. 317 
Apoptosis and necrosis levels are expressed as percentage of the total cell population and given as mean ± 318 
SD (n=5). Percentage of cells in different phases (G0/G1, S and G2/M phases) are expressed as mean ± SD 319 
(n=3). Asterisks represent significant differences between test concentrations and DMSO control. *p ≤ 0.05, 320 
**p ≤ 0.01,*** p ≤ 0.001, **** p ≤ 0.0001. 321 
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3.5. Bioassay guided fractionation of T. bentzoë leaf extract 322 
3.5.1. Effect of T. bentzoë fractions on HepG2 cell viability 323 
HepG2 cells were used as a model to fractionate and characterise the bioactive components 324 
present in T. bentzoë leaf extract. The first round of fractionation was achieved using liquid-liquid 325 
portioning with organics solvents of increasing polarities. T. bentzoë butanol fraction, being most 326 
active, was further fractionated on a Sephadex LH-20 column. A total of 11 sub-fractions was derived 327 
with cytotoxic activity being limited between fractions F4 to F10 only (Table 5). Assessment of their 328 
chromatographic patterns revealed differences in the chemical compositions of the fractions, albeit 329 
multiple overlapping peaks highlighting the chemical complexity of the subfractions. Given the most 330 
potent cytotoxic activity of the subfraction F6 (IC50 = 15.2 ± 1.8 µg/mL), the further fractional 331 
separation of the latter was achieved using preparative HPLC to yield 11 HPLC subfractions (F6.1 – 332 
F6.11). Of these, HPLC subfraction F6.1 retained most of the cytotoxic activity, providing an IC50 value 333 
of 15.8 ± 0.3 µg/mL. By contrast, HPLC fractions F.2, F.7, F.9, F.10 and F.11 failed to effectively inhibit 334 
the growth of HepG2 cell cultures; hence no IC50 values were determined for these subfractions. A 335 
summary of the bioassay-guided fractionation employed is depicted in figure 3.   336 
 337 
 338 
Figure 3. MTT- guided fractionation of T. bentzoë extract cytotoxicity against HepG2 cells. Cmpd: 339 
Compound. Cmpd 1= α and β- Punicalagin; compd 2= Isoterchebulin; compd 3 = Terflavin A; cmpd 4 340 
= 3,4,6-trigalloyl-β-D-glucopyranose, cmpd 5 = 2"-O-galloyl-orientin; cmpd 6 = 2"-O-galloyl-341 
isoorientin. 342 
3.5.2. Antioxidant potential of T. bentzoë fractions 343 
Both the ethyl acetate (22 ± 0.29 mmol Fe2+) and butanol (21.01 ± 0.56 mmol Fe2+) fractions were 344 
significantly (p ≤ 0.05) higher compared to the aqueous residual fraction. Furthermore, the FRAP 345 
value of the organic fractions was greater as compared to the total extract. The butanol fraction of T. 346 
bentzoë was a more effective scavenger of DPPH• radical as opposed to ethyl acetate and aqueous 347 
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residual fractions (Table 5). As far as the butanol subfractions were concerned, notably F6, F7, and 348 
F8 had better antioxidant activity in FRAP and superoxide radical scavenging assays (Table 5). 349 
3.6. Characterisation of the cytotoxic components of T. bentzoë. 350 
In an effort to identify the bioactive constituents in T. bentzoë, bioassay-guided fractionation was 351 
carried out. LC-MS analysis in conjunction with NMR spectroscopy of T. bentzoë butanol fraction 6 352 
and its semi-prep HPLC sub-fractions allowed the identification of 8 phenolic compounds including 353 
α and β-punicalagin (1), isoterchebulin (2), terflavin A (3), 3,4,6-trigalloyl-β-D-glucopyranose (4), 2"-354 
O-galloyl-orientin (5), 2"-O-galloyl-isoorientin (6), 2”-O-galloylvitexin (7), and ellagic acid (8) (Figure 355 
4, Table 6, Supplementary Figures S4). The bioactive HPLC subfractions F6.1 (IC50 value = 15.8 ± 0.3 356 
µg/mL) revealed to be α and β- punicalagin (1) (Supplementary Figures S5), while a mixture of 357 
isoterchebulin (2), terflavin A (3), and 3,4,6-trigalloyl-β-D-glucopyranose (4) (Supplementary Figures 358 
S6) was identified from the active subfraction F6.6 (IC50 value = 19.6 ± 0.7 µg/mL). A mixture of 2"-O-359 
galloyl-orientin (5) and 2"-O-galloyl-isoorientin (6) (Supplementary Figures S7 and Table S1), with 360 
a ratio of 5:2 based on the 1H NMR integration of single hydrogen in each compound was identified 361 
from the non-active subfraction F6.9. 2”-O-galloylvitexin (7), and ellagic acid (8) were detected only 362 
by LC-MS from the butanol fraction 6 (Supplementary Figures S4). Additionally, two simple 363 
phenolics, gallic acid and methyl gallate were detected in both the ethyl acetate and butanol fractions 364 
and identified by GC-MS analysis (Supplementary figure S8). They were likely present in other less 365 
bioactive fractions. The levels of gallic and methyl gallate were quantified as 15.6 ± 1.1 and 26.2 ± 8.1 366 
µg/mg total extract) (n=3) by HPLC, respectively. 367 
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 368 
Figure 4. Chemical structure of polyphenolic compounds (1-8) identified in Terminalia bentzoë L. leaf 369 
extract. 370 
  371 
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Table 5. Cytotoxic and antioxidant potential of T. bentzoë leaf fractions and the isolated punicalagin 372 
(1). 373 
T. bentzoë Fractions 
IC50 
(µg/mL) 
against 
HepG2 
cells 
FRAP1 DPPH2 
Superoxide 
scavenging 
activity2 
Ethyl acetate 20.8 ± 0.1 21.98 ± 0.29a,b 1.17 ± 0.02d,e 7.43 ± 0.14b 
Butanol 18.3 ± 3.4 21.01 ± 0.56b,c 0.98 ± 0.06e 7.65 ± 0.10b 
Aqueous residual 26.8 ± 5.5 15.29 ± 0.16e 1.78 ± 0.07b,c 10.70 ± 0.20a,b 
T.
bn
et
zo
e 
bu
ta
no
l s
ub
fr
ac
tio
ns
 
F1 ND 3.04 ± 0.10g ND ND 
F2 ND 13.62 ± 0.16f 2.65 ± 0.04a 16.90 ± 0.35a 
F3 ND 13.80 ± 0.14e,f 1.79 ± 0.12b,c 10.80 ± 0.28a,b 
F4 28.9 ± 1.5 14.42 ± 0.27e,f 2.09 ± 0.08b 8.96 ± 0.12b 
F5 25.7 ± 2.9 18.46 ± 0.15d 1.71 ± 0.07c 8.71 ± 0.10b 
F6 15.7 ± 1.8 23.01 ± 0.68a 1.19 ± 0.09d,e 7.03 ± 0.20b 
F7 19.9 ± 4.7 20.94 ± 0.49b,c 1.01 ± 0.07d,e 7.15 ± 0.18b 
F8 24.6 ± 5.9 19.86 ± 0.29c,d 1.12 ± 0.06d,e 8.76 ± 0.08b 
F9 22.3 ± 3.1 18.82 ± 0.31d 0.99 ± 0.06e 9.33 ± 0.24b 
F10 26.7 ± 6.2 18.47 ± 0.28d 1.34 ± 0.04d 9.05 ± 0.23b 
F11 ND 0.09 ± 0.02h ND ND 
A
ct
iv
e 
H
PL
C
 
su
bf
ra
ct
io
ns
 F6.1 (Punicalagin (1)) 15.8 ± 0.3 - - - 
F6.3 27.5 ± 0.8 - - - 
F6.4 17.4 ± 0.4 - - - 
F6.5 22.1 ± 0.6 - - - 
F6.6 19.6 ± 0.7 - - - 
F6.8 18.6 ± 0.4 - - - 
 374 
1Values are expressed in units of mmol Fe2+/gFDW; 2Values are expressed in units of µg/mL; Data 375 
represent mean with a standard error of the mean (n=3). Different letters between rows in each column 376 
represent significant differences between extracts (p <0.05). ND = IC50 value not reached at maximun 377 
test dose. “-“ = Not tested. 378 
Table 6. Identification of phenolic compound in T. bentzoë butanol fraction F6 using high-resolution 379 
mass spectrometry, NMR spectroscopy, and comparison with literature and available data. 380 
Compound 
number RT/min 
Negative ESI-
MS [M-H]- 
Molecular 
formula Compound References 
1 0.76 1083.0555 C48H28O30 Punicalagin  [33–36]  
2 4.08 1083.0555 C48H28O30 Isoterchebulin  [33]  
3 4.58 1085.0710 C48H30O30 Terflavin A [37]  
4 4.97 635.0867 C27H24O18 3,4,6-trigalloyl-β-D-glucopyranose [38]  
5 6.25 599.1017 C28H24O15 2"-O-galloyl-orientin [34]  
6 6.25 599.1017 C28H24O15 2"-O-galloyl-
isoorientin 
[34] 
7 6.53 583.1074 C28H24O14 2”-O-Galloylvitexin  [34,35] 
8 6.72 300.9987 C14H6O8 Ellagic acid [33] 
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4. Discussion 381 
Medicinal plants are known to be the epicentre of numerous well established ethnomedicinal 382 
systems across the globe [4]. However, more than 84 % of these medicinal plants have been poorly 383 
studied in regards to their phytochemical compositions, clinical efficacy as well as their safety and 384 
toxicological profiles [4]. Moreover, forest cover is being uprooted across the world, at an 385 
unprecedented rate, threatening the survival of at least 15000 medicinal plant species [39]. Plant 386 
secondary metabolites have contributed enormously to the modern-day pharmaceutical industry by 387 
providing the chemical backbone for almost 25 % of the 1562 clinical agents as well as 60 % of the 246 388 
oncologic drugs approved by the US Federal Drugs Administration between 1981 and 2014 [1,2,40]. 389 
As such it is of utmost importance to evaluate the unexplored terrestrial flora for their therapeutic 390 
potential, as the dwindling medicinal plant's species continues to stand as a rich repository to probe 391 
for novel chemotypes in the drug developmental process.  392 
The current findings highlighted the richness of the different subclasses of polyphenolics, 393 
notably phenolics, flavonoids and proanthocyanidins, the distribution of which differed significantly 394 
(p < 0.05) among the investigated accessions (Table 2). The biosynthesis of flavonoids, in particular 395 
flavonols, are known to be upregulated in response to ultra-violet radiation [41]. The accumulation 396 
of flavonoids in the endemic plant leaves collected from Mauritius may be attributed to the high 397 
sunlight conditions and UV radiation which are characteristic to tropical islands like the Mascarene 398 
[42].  399 
Given the ubiquitous involvement of oxidative damage in carcinogenesis, antioxidant-rich 400 
secondary metabolites, notably, polyphenolics have attracted much interest in the search of novel 401 
and alternative treatment modalities for cancer [43,44]. In this vein, the in vitro antioxidant activities 402 
often correlated strongly with the growth inhibitory activity against cancer cell lines [45,46]. 403 
However, it is crucial to note that both ROS and antioxidants have a “Janus-faced” effect in cancer 404 
management, as their effect differs in the early events of cancer initiation, from those involved in the 405 
survival and propagation of an establish tumors [43,47]. On one hand, where moderate ROS level 406 
promotes the transformation of a normal cell to malignant cells, elevating the ROS level in cancer 407 
cells beyond the cell tolerance threshold may promote oxidative stress-induced cell cytotoxicity [47–408 
49]. It should be noted that many standard chemotherapies cause cancer cell death via generation of 409 
ROS and excessive oxidation [50], therefore the effect of antioxidant polyphenols in combination with 410 
these chemotherapies on cancers must be fully evaluated in vitro and in vivo before use in patients.  411 
The antioxidant mechanism of action of polyphenols are multifaceted, thus a panel of in vitro 412 
assay models allowed to gauge the antioxidant potential of the evaluated extracts [51]. T. bentzoë 413 
having the highest abundance of total phenolics and flavonoids also exhibited the most potent 414 
antioxidant activity in all six in vitro assays and was further evaluated for its cytotoxicity against 415 
cancer cell lines. However, the other six plant species might also show cytotoxicity through different 416 
mechanisms, which were not investigated in this study.  417 
The cytotoxicity of different Terminalia species against multiple cancerous cell lines is 418 
documented. Investigation of the cytotoxic activity of methanolic leaf extracts of T. arjuna against 419 
human chronic myelogenous leukaemia cells led to the isolation of the bioactive ursolic acid 420 
(triterpenoid) [52]. Leaf extracts of T. chebula suppressed the growth of human breast and lung cancer 421 
cell lines [53]. Along a similar line, the leaf extract from T. catappa significantly (p < 0.05) suppressed 422 
the proliferation of human colorectal (SW480) cell line in a dose-dependent manner by 423 
downregulating the level of B-cell lymphoma 2 (BCL-2) gene expression while upregulating the level 424 
of Caspase 9 and Caspase 3, indicative of the mitochondrial pathway of apoptosis in SW480 cells [54]. 425 
The foremost aim of oncologic agents is to precisely target cancerous cells with minimal effect 426 
on non-malignant cells. T. bentzoë crude extract had a selective index value of approximately 2.5, 427 
indicating that the extract had some degree of selectivity towards HepG2 cells as opposed to non-428 
malignant human ovarian epithelial cells. Nevertheless, it is crucial to also assess the cytotoxicity of 429 
the extract against a panel of normal cells of different tissue origins, to provide greater insight 430 
regarding its toxicity window and safety profile.  431 
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In line with the United States National Cancer Institute cytotoxicity guidelines [55,56], T. bentzoë 432 
crude extract with an IC50 value of 22.8 ± 1.3 µg/mL can be considered as a potent candidate for further 433 
investigation with regards to its anticancer potential. It is known that, following exposure to 434 
toxicants, a subpopulation of cells enters a dormant state. These dormant viable cells further retained 435 
their ability to replicate into stem-like progeny cells which might lead to the development of drug-436 
resistance and cancer relapse [57,58]. Thus, while investigating the potential anticancer effect of 437 
extracts, it is warranted to also evaluate their long-term effect on the replicative ability of the cancer 438 
cell line. The colony formation assay is a simple and useful in vitro model, considered as the gold 439 
standard to predict the long-term sensitivity of cancer cell response to therapeutics treatment [57,59]. 440 
In this vein, the current study evidenced the ability of T. bentzoë to impede the replicative potential 441 
of HepG2 cells (Figure 1). Numerous anticancer agents, including polyphenols, are known to 442 
abrogate the limitless replicative ability of different cancer cell variants [60,61]. Catechin, catechin-3-443 
O-gallate, 7-O-galloyl catechin, and methyl gallate purified from Acasis hydaspica is reported to 444 
suppress the long-term clonal proliferation of prostate cancer (PC-3) cells [62]. 445 
This study also attempted to delineate the mode of T. bentzoë induced HepG2 cell death.  Flow 446 
cytometric analysis of annexin V-FITC and PI dual stained HepG2 cells treated with 40 µg/mL, 447 
revealed a significant (p < 0.05) increased in both Annexin V-FITC and PI fluorescence level, 448 
compared to the untreated control, thus indicating the putative activation of both apoptotic and 449 
necrotic pathways in HepG2 cells. Cells grown as monoculture are known to initiate apoptosis which 450 
is terminated by necrosis like events, also termed as secondary necrosis, due to the absence of 451 
phagocytic scavenger cells [63,64]. Numerous studies evidenced this type of cancer cell death 452 
following treatment with cytotoxic agents. Ellagic acid was reported to induce both apoptotic and 453 
necrotic cell death mechanism in human pancreatic cancer cell cultures [65]. A similar effect of 454 
Lepidium sativum and Vitis vinifera extract were highlighted in human breast and skin cancer cells, 455 
respectively [66,67]. 456 
Plant extracts and/or thereby derived phytochemicals are known to provoke cancer cell death 457 
by causing oxidative damage to genetic material mediated cell cycle arrest and subsequent cell death 458 
[68,69].  With this in mind, the DNA damage to HepG2 cellular DNA following T. bentzoë crude 459 
extracts treatment was investigated using the alkaline comet assay and scored in terms of tail length, 460 
tail intensity, and olive tail moment. The comet assay is a well-established and highly sensitive 461 
method for the detection of DNA damage and fragmentation pattern [70]. T. bentzoë induced 4 folds 462 
significantly (p < 0.001) higher DNA damaged to HepG2 cells compared to the untreated control, as 463 
reflected by the olive tail moments (Table 4). Consistent with the DNA damaging ability, T. bentzoë 464 
halted the cell cycle progression significantly (p < 0.01, versus control) in the G0/G1 phase (Figure 2). 465 
A similar observation was reported in lung cancer cells, where casuarinin, a tannin purified from T. 466 
arjuna L. bark, provoked apoptotic mechanism via DNA fragmentation and G0/G1 phase cell cycle 467 
arrest [71].  468 
It is noteworthy that, the cytotoxicity of the extract may arise from the complex interplay of the 469 
cocktails of secondary metabolites present, which may act either synergistically or antagonistically to 470 
produce the overall results. Also, crude extracts often comprised a pool of inactive phytoconstituents 471 
that dilute the efficacy of the active components [72,73]. It is therefore of paramount importance to 472 
purify and identify the principal bioactive components to conduct further mechanistic studies to 473 
establish their molecular mode of action [72,74]. Moreover, isolating the lead compounds also allows 474 
for the potential structural modification in an attempt to enhance their selectivity and potency [75]. 475 
As such, the MTT-guided fractionation revealed that only six out of the eleven preparative HPLC 476 
subfractions retained the potent cytotoxicity of the crude extract (Figure 3). The HPLC subfraction 477 
F6.1 was 1.4 folds more potent as compared to the crude extract.  478 
LC-MS analysis in conjunction with NMR spectroscopy allowed the identification of 8 phenolic 479 
compounds from the most bioactive subfraction F6. Punicalagin, isoterchebulin and ellagic acid have 480 
been previously reported from the bark extract of the same species collected in Réunion Island [33]. 481 
Although, the other identified compounds are being reported for the first time, to the best of our 482 
current knowledge, in T. bentzoë leaf, some were reported in the leaf extracts of other Terminalia 483 
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species. For instance, 2”-O-galloylvitexin and gallic acid were identified from T. brachystemma Welw. 484 
ex Hiern and T. mollis M. Laws leaves, respectively [35]. Likewise, terflavin A was found in  T. 485 
catappa L. leaf [37].  486 
Punicalagin and ellagic acid were reported to induce S Phase arrest and G0/G1 phase arrest in 487 
HepG2 cells, respectively [76]. Moreover, punicalagin induced G0/G1 phase arrest in papillary 488 
human thyroid carcinoma (BCPAP) cells via the NF-κB signaling pathway [77]. In human ovarian 489 
cancer (A2780) cells, punicalagin treatment was associated with an increase in the number of cells 490 
arrested at G1/S phase as well as the downregulation of the β-catenin signaling pathway [78].  Ellagic 491 
acid administration in prostate cancer patients was associated with decreased prostate-specific 492 
antigen as well as reduced chemotherapy-induced myelotoxicity [79]. It may be strongly proposed 493 
that the overall cytotoxicity of T. bentzoë leaf extract may be a synergistic effect of the identified 494 
compounds. Gallic acid was reported to induce S phase arrest in HepG2 cells [80] and be cytotoxic to 495 
ovarian cancer cells [81]. Furthermore, gallic acid was also shown to impair centrosomal clustering 496 
in human cervical cancer (Hela) cells, thus causing a mitotic catastrophe and ultimate cell G2/M phase 497 
cell cycle arrest.  498 
5. Conclusion 499 
The findings evidenced the selective long-term cytotoxicity of the antioxidant-rich T. bentzoë leaf 500 
extract against HepG2 cells. This plant which is also used traditionally in the mitigation of asthma, 501 
haemorrhages, diarrhoea, and sexually transmissible diseases, amongst others, has also shown some 502 
in-vitro anticancer activities against HepG2 cells. The cytotoxic nature of T. bentzoë leaf extract against 503 
cancerous cells indicated that T. bentzoë leaf has the potential to be repurposed in the mitigation of 504 
cancer as part of traditional medicine. The results so far generated, supports the hypothesis that T. 505 
bentzoë extract induced apoptosis/necrosis cell death in HepG2 cells via the degradation of cellular 506 
genetic material and subsequent arrest of the cell cycle progression in G0/G1 phase. Overall, the MTT-507 
guided fractionation of the crude extract allowed the characterisation of 10 phenolic compounds 508 
including punicalagin, ellagic acid, gallic acid, and methyl gallate that are known to have established 509 
in vitro and in vivo anticancer activities. However, the contribution of the other non-identified 510 
phytoconstituents cannot be excluded and thus further evaluation of identified components is 511 
warranted alongside the crude extract. The metabolite profiling of the leaf extract may be envisaged 512 
in future studies. This will allow to precisely ascribe the bioactive molecules present in T. bentzoë leaf. 513 
Taking into consideration the guidelines of the US national cancer institute as well as the selectivity 514 
index observed in this study, T. bentzoë leaf extract revealed as a promising candidate that can be 515 
exploited in the search for novel anticancer agents. The current study provided base line data for 516 
more in-depth investigations of the chemotherapeutic potential of T. bentzoë plant extracts. Further 517 
mechanistic investigation, directed towards delineating the molecular mechanisms via which the 518 
purified bioactive entities target of the aberrant signaling pathways involved in carcinogenesis, is 519 
needed to fuel in-vivo studies. Future animal studies and ideally human clinical trials are warranted 520 
to establish the physiological doses for human administration. 521 
Supplementary Materials: Figure S1: Cell viability profile of HepG2 cells treated with T. bentzoë extract and 522 
fractions. Figure S2: Representatives annexin V-FITC/PI flow cytometric profile of HepG2 cells, 48 hours post 523 
extract/control treatment. Figure S3: Representatives cell cycle histogram of HepG2 cells, 48 hours post 524 
extract/control treatment. Figure S4: UPLC ESI MS of the butanol fraction 6 at the positive (A) and negative (B) 525 
mode. Figure S5: 1H NMR spectrum (A) and HSQC spectrum (B) for punicalagin (1) in an HPLC fraction at RT 526 
2-3 min in methanol-d4. Figure S6: 1H NMR spectra for a mixture of isoterchebulin (2), terflavin A (3), and 3,4,6-527 
trigalloyl-beta-D-glucopyranose (4) in a HPLC fraction at RT18-20 min in acetone-d6 (A) and methanol-d4 (B). 528 
Figure S7: 1H NMR spectra for a mixture of 2"-O-galloyl-orientin (3) and 2"-O-galloyl-isoorientin (6) with a ratio 529 
of 5:2 based on the integration of single hydrogen in each compound. Figure S8: GC –MS chromatogram of TMSi 530 
derivatives of ethyl acetate (A) and butanol (B) fraction of T. bentzoë. Table S1 1H NMR spectral data (500 MHz, 531 
CD3OD) of the O-galloyl-C-glycosylflavones 7 and 8 (5:2) [" in ppm, multiplicities and J values (Hz) are given in 532 
parentheses]. 533 
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